| Literature DB >> 33277786 |
Takeshi Nishikawa1, Hiroyuki Kinoshita1, Keiko Ono1, Shoko Kodama-Hashimoto1, Yuka Kobayashi1, Tomofumi Nakamura1, Tomoaki Yoshinaga1, Yuma Ohkubo1, Masahiro Harada2, Tetsushi Toyonaga3, Takeshi Takahashi1, Eiichi Araki4.
Abstract
AIMS/Entities:
Keywords: Coagulation disorders; Diabetic ketoacidosis; Hyperglycemic hyperosmotic syndrome
Mesh:
Substances:
Year: 2021 PMID: 33277786 PMCID: PMC8354495 DOI: 10.1111/jdi.13475
Source DB: PubMed Journal: J Diabetes Investig ISSN: 2040-1116 Impact factor: 4.232
Characteristics of patients with hyperglycemic crises
| DKA ( | HHS ( | MIX ( | |||||
| Age (years) | 49.4 ± 19.7 | (87) | 74.6 ± 14.9** | (38) | 64.9 ± 21.1** | (19) | <0.001 |
| BMI | 22.7 ± 6.2 | (85) | 20.4 ± 4.6 | (35) | 21.9 ± 5.2 | (19) | 0.148 |
| Male, | 47 (54.0) | (87) | 20 (52.6) | (38) | 16 (84.2)§ | (19) | 0.037 |
| Type of diabetes mellitus | |||||||
| Type 1, | 40 (46.0)¶ | (87) | 0 (0.0)‡ | (38) | 5 (26.3) | (19) | <0.001 |
| Type 2, | 34 (39.1)‡ | (87) | 36 (94.7)¶ | (38) | 13 (68.4) | (19) | |
| Secondary, | 10 (11.5) | (87) | 1 (2.6) | (38) | 1 (5.3) | (19) | |
| Unknown, | 3 (3.4) | (87) | 1 (2.6) | (38) | 0 (0.0) | (19) | |
| Treatment of diabetes mellitus before the onset of hyperglycemic crises | |||||||
| No medication, | 31 (35.6)† | (87) | 22 (57.9)§ | (38) | 9 (47.4) | (19) | 0.004 |
| Oral antidiabetic drugs only, | 15 (17.2) | (87) | 11 (28.9) | (38) | 5 (26.3) | (19) | |
| Insulin only, | 36 (41.4)¶ | (87) | 3 (7.9)‡ | (38) | 3 (15.8) | (19) | |
| GLP‐1 only, | 0 (0.0) | (87) | 0 (0.0) | (38) | 0 (0.0) | (19) | |
| Insulin with oral antidiabetic drugs, | 4 (4.6) | (87) | 2 (5.3) | (38) | 2 (10.5) | (19) | |
| GLP‐1 with oral antidiabetic drugs, | 0 (0.0) | (87) | 0 (0.0) | (38) | 0 (0.0) | (19) | |
| Insulin with GLP‐1, | 0 (0.0) | (87) | 0 (0.0) | (38) | 0 (0.0) | (19) | |
| Insulin with GLP‐1 and oral antidiabetic drugs, | 1 (1.1) | (87) | 0 (0.0) | (38) | 0 (0.0) | (19) | |
| Precipitating causes (with multiple selections) | |||||||
| Newly diagnosed diabetes mellitus, | 26 (29.9) | (87) | 12 (31.6) | (38) | 8 (42.1) | (19) | 0.598 |
| Discontinuation of medications, | 43 (49.4)¶ | (87) | 6 (15.8)f | (38) | 8 (42.1) | (19) | 0.001 |
| Infection, | 43 (49.4) | (87) | 26 (68.4) | (38) | 11 (57.9) | (19) | 0.136 |
| Overconsumption of sugar‐containing soft drinks, | 21 (24.1) | (87) | 3 (7.9)‡ | (38) | 9 (47.4)¶ | (19) | 0.003 |
Data are the mean ± standard deviation, (n). **P < 0.01 versus DKA. †Adjusted standardized residual <−1.96 (significance level P = 0.05). ‡Adjusted standardized residual <−2.58 (significance level P = 0.01). §Adjusted standardized residual >1.96 (significance level P = 0.05). ¶Adjusted standardized residual >2.58 (significance level P = 0.01).
BMI, body mass index; GLP‐1, glucagon‐like peptide‐1; MIX, mixed diabetic ketoacidosis/hyperglycemic hyperosmolar state.
Levels of consciousness in patients with hyperglycemic crises
| DKA ( | HHS ( | MIX ( | ||
| JCS grade 0, | 40 (46.0)¶ | 1 (2.6)‡ | 1 (5.3)† | <0.001 |
| JCS grade 1, | 27 (31.0) | 16 (42.1) | 6 (31.6) | |
| JCS grade 2, | 12 (13.8)† | 9 (23.7) | 8 (42.1)¶ | |
| JCS grade 3, | 8 (9.2)‡ | 12 (31.6)¶ | 4 (21.1) |
†Adjusted standardized residual <−1.96 (significance level P = 0.05). ‡Adjusted standardized residual <−2.58 (significance level P = 0.01). ¶Adjusted standardized residual > 2.58 (significance level P = 0.01).
DKA, diabetic ketoacidosis; HHS, hyperglycemic hyperosmolar state; JCS, Japan Coma Scale; JCS grade 0, alert; JCS grade 1, possible eye‐opening, not lucid; JCS grade 2, possible eye‐opening upon stimulation; JCS grade 3, no eye‐opening and coma; MIX, mixed diabetic ketoacidosis/hyperglycemic hyperosmolar state.
Laboratory data of patients with hyperglycemic crises
| DKA ( | HHS ( | MIX ( | Reference range | |||||
|---|---|---|---|---|---|---|---|---|
| Glucose (mg/dL) | 660.1 ± 274.4 | (87) | 911.0 ± 258.0‡ | (38) | 1175.2 ± 400.2‡,¶ | (19) | <0.001 | 70–109 |
| HbA1c (%) | 11.22 ± 3.14 | (86) | 9.62 ± 2.19† | (36) | 12.16 ± 3.36§ | (18) | 0.005 | 4.9–6.0 |
| Effective osmolarity (mOsm/L) | 294.4 ± 13.4 | (87) | 357.0 ± 25.8‡ | (38) | 342.9 ± 19.2‡,§ | (19) | <0.001 | |
| Na (mEq/L) | 128.9 ± 7.5 | (87) | 153.2 ± 13.3‡ | (38) | 138.8 ± 10.7‡,¶ | (19) | <0.001 | 138–145 |
| K (mEq/L) | 5.09 ± 1.19 | (87) | 4.36 ± 0.82‡ | (38) | 5.05 ± 1.16 | (19) | 0.003 | 3.6–4.8 |
| Cl (mEq/L) | 93.8 ± 9.6 | (87) | 112.8 ± 12.2‡ | (38) | 97.5 ± 12.4¶ | (19) | <0.001 | 101–108 |
| eGFR | 63.74 ± 54.35 | (84) | 31.32 ± 17.59‡ | (38) | 23.76 ± 12.98‡ | (19) | <0.001 | 60.0‐ |
| Ketone bodies in urine | 2.97 ± 1.22 | (86) | 0.39 ± 0.74‡ | (38) | 1.53 ± 1.15‡,¶ | (19) | <0.001 | |
| Total ketone bodies in blood (μmol/L) | 12181.8 ± 4860.3 | (44) | 11342.8 ± 5736.8 | (11) | 0.623 | 0–130 | ||
| pH | 7.113 ± 0.168 | (87) | 7.395 ± 0.074‡ | (37) | 7.113 ± 0.159¶ | (19) | <0.001 | 7.35–7.45 |
| Bicarbonate ion (mmol/L) | 7.43 ± 4.76 | (84) | 26.61 ± 7.94‡ | (37) | 9.57 ± 5.60¶ | (18) | <0.001 | 23–28 |
| Lactate (mmol/L) | 3.09 ± 2.36 | (87) | 3.23 ± 1.76 | (37) | 4.77 ± 3.45† | (19) | 0.023 | |
| CRP (mg/dL) | 6.782 ± 11.753 | (84) | 3.850 ± 4.783 | (37) | 4.453 ± 5.654 | (18) | 0.265 | 0.00–0.14 |
| PCT (ng/mL) | 3.431 ± 7.484 | (36) | 0.759 ± 0.895 | (18) | 7.444 ± 10.336 | (8) | 0.073 | 0.00–0.50 |
| WBC (/μL) | 16724.6 ± 8947.6 | (87) | 13635.8 ± 7116.6 | (38) | 17204.2 ± 5547.0 | (19) | 0.119 | 3300–8600 |
| Hb (g/dL) | 13.94 ± 2.62 | (87) | 14.37 ± 2.83 | (38) | 15.19 ± 2.36 | (19) | 0.166 | 13.7–16.8 |
| PLT (×104/μL) | 24.56 ± 9.28 | (86) | 22.12 ± 8.12 | (38) | 24.66 ± 11.05 | (19) | 0.374 | 15.8–34.8 |
| PT‐INR | 1.114 ± 0.165 | (77) | 1.309 ± 0.602† | (36) | 1.101 ± 0.080 | (19) | 0.014 | 0.85–1.15 |
| Fibrinogen (mg/dL) | 400.2 ± 196.3 | (35) | 398.6 ± 115.3 | (17) | 363.0 ± 137.1 | (12) | 0.794 | 200–400 |
| FDP (μg/mL) | 7.94 ± 8.43 | (38) | 35.54 ± 51.80‡ | (24) | 17.61 ± 31.49 | (14) | 0.007 | 0.0–5.0 |
| D‐dimer (μg/mL) | 2.830 ± 2.745 | (38) | 14.846±21.430‡ | (22) | 6.230 ± 10.669 | (13) | 0.003 | 0.00–1.00 |
Data are the mean ± standard deviation. † P < 0.05 versus diabetic ketoacidosis (DKA). ‡ P < 0.01 versus DKA. § P < 0.05 versus hyperglycemic hyperosmolar state (HHS). ¶ P < 0.01 versus HHS.
CRP, C‐reactive protein; eGFR, estimated glomerular filtration rate; FDP, fibrin and fibrinogen degradation products; Hb, hemoglobin; HbA1c, glycated hemoglobin; MIX, mixed diabetic ketoacidosis/hyperglycemic hyperosmolar state; PCT, procalcitonin; PLT, platelets; PT‐INR, prothrombin time‐international normalized ratio; WBC, white blood cells.
Rates of mortality and arterial or vein diseases in patients with hyperglycemic crises
| DKA ( | HHS ( | MIX ( | ||
|---|---|---|---|---|
| Dead, | 5 (5.7) | 5 (13.2) | 1 (5.3) | 0.320 |
| Acute arterial occlusive disease, | 0 (0.0)‡ | 3 (7.9) | 4 (21.1)¶ | <0.001 |
| Venous thrombosis, | 1 (1.1) | 2 (5.3) | 2 (10.5) | 0.059 |
‡Adjusted standardized residual <−2.58 (significance level P = 0.01). ¶Adjusted standardized residual >2.58 (significance level P = 0.01).
DKA, diabetic ketoacidosis; HHS, hyperglycemic hyperosmolar state; MIX, mixed diabetic ketoacidosis/hyperglycemic hyperosmolar state.
Logistic regression analysis with selected independent variables
| B | Standard error | Odds ratio (95% CI) | ||
|---|---|---|---|---|
| Age (years) | −0.007 | 0.024 | 0.752 | 0.993 (0.948–1.040) |
| JCS grade | −0.811 | 0.570 | 0.155 | 0.445 (0.145–1.359) |
| pH | −3.457 | 2.934 | 0.239 | 0.032 (0.000–9.901) |
| Effective osmolarity (mOsm/L) | −0.003 | 0.028 | 0.911 | 0.997 (0.943–1.054) |
| Na (mEq/L) | 0.079 | 0.070 | 0.256 | 1.082 (0.944–1.241) |
| PT‐INR | 4.910 | 1.738 | 0.005 | 135.705 (4.498–4094.003) |
| CRP (mg/dL) | 0.063 | 0.032 | 0.046 | 1.066 (1.001–1.134) |
CI, confidence interval; CRP, C‐reactive protein; JCS, Japan Coma Scale; PT‐INR, prothrombin time‐international normalized ratio.